Cystic fibrosis and congenital agenesis of the vas deferens, antisperm antibodies and CF-genotype. 1994

M H Vazquez-Levin, and G S Kupchik, and Y Torres, and C A Chaparro, and A Shtainer, and R J Bonforte, and H M Nagler
Department of Urology, Beth Israel Medical Center, New York, NY 10003, USA.

Antisperm antibodies are formed as a result of vasal and epididymal obstruction. Fourteen males of different ages (pre-, peri- and post-pubertal) with bilateral congenital vasal agenesis and epididymal obstruction secondary to cystic fibrosis (CF), and seven men with congenital bilateral aplasia of the vas deferens (CBAVD) were evaluated with regard to both the presence and levels of serum antisperm antibodies, and the CF-genotype. While IgA and IgG were not detected among pre- and peri-pubertal CF patients, 4 out of 10 (40%) exhibited IgM binding to sperm tail-tip. Post-pubertal CF patients showed high antisperm antibody (ASA) levels in 3 of the 4 males (75%) evaluated for the three isotypes assayed. ASA were found in 5 of 7 CBAVD patients (71%); IgG (n = 3) and IgM (n = 4) were found to be the predominant isotypes bound to sperm tail-tip. CF-genotype analysis revealed two pre-pubertal patients with the DeltaF508/DeltaF508 CF-genotype and a positive ASA response, thus suggesting an earlier or more severe blockage. In addition, the two CBAVD patients found to have a ?/? CF-genotype on the initial screening did not have ASA. The altered antigenicity of sperm associated with initiation of spermatogenesis appears to modify the antisperm antibody isotypes. Further studies on a larger number of patients may allow for a better understanding of the ASA response, as well as a better understanding of a possible phenotype/genotype association between the CF-genotype and the immunologic response.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D011627 Puberty A period in the human life in which the development of the hypothalamic-pituitary-gonadal system takes place and reaches full maturity. The onset of synchronized endocrine events in puberty lead to the capacity for reproduction (FERTILITY), development of secondary SEX CHARACTERISTICS, and other changes seen in ADOLESCENT DEVELOPMENT. Puberties
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M H Vazquez-Levin, and G S Kupchik, and Y Torres, and C A Chaparro, and A Shtainer, and R J Bonforte, and H M Nagler
July 1995, Der Urologe. Ausg. A,
M H Vazquez-Levin, and G S Kupchik, and Y Torres, and C A Chaparro, and A Shtainer, and R J Bonforte, and H M Nagler
September 1997, Actas urologicas espanolas,
M H Vazquez-Levin, and G S Kupchik, and Y Torres, and C A Chaparro, and A Shtainer, and R J Bonforte, and H M Nagler
June 1996, Contraception, fertilite, sexualite (1992),
M H Vazquez-Levin, and G S Kupchik, and Y Torres, and C A Chaparro, and A Shtainer, and R J Bonforte, and H M Nagler
February 2003, Minerva pediatrica,
M H Vazquez-Levin, and G S Kupchik, and Y Torres, and C A Chaparro, and A Shtainer, and R J Bonforte, and H M Nagler
July 1991, The New England journal of medicine,
M H Vazquez-Levin, and G S Kupchik, and Y Torres, and C A Chaparro, and A Shtainer, and R J Bonforte, and H M Nagler
June 1998, Archivos espanoles de urologia,
M H Vazquez-Levin, and G S Kupchik, and Y Torres, and C A Chaparro, and A Shtainer, and R J Bonforte, and H M Nagler
May 1992, Lancet (London, England),
M H Vazquez-Levin, and G S Kupchik, and Y Torres, and C A Chaparro, and A Shtainer, and R J Bonforte, and H M Nagler
September 1969, Lancet (London, England),
M H Vazquez-Levin, and G S Kupchik, and Y Torres, and C A Chaparro, and A Shtainer, and R J Bonforte, and H M Nagler
June 1996, The Journal of urology,
M H Vazquez-Levin, and G S Kupchik, and Y Torres, and C A Chaparro, and A Shtainer, and R J Bonforte, and H M Nagler
January 1995, Lancet (London, England),
Copied contents to your clipboard!